Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

A Phase 2 Study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.

Hajek R, Pour L, Ozcan M, Martin Sánchez J, García Sanz R, Anagnostopoulos A, Oriol A, Cascavilla N, Terjung A, Lee Y, Briso EM, Dobkowska E, Hauns B, Špička I.

Eur J Haematol. 2019 Dec 28. doi: 10.1111/ejh.13377. [Epub ahead of print]

PMID:
31883396
2.

Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.

Stork M, Sandecká V, Boichuk I, Adam Z, Krejci M, Brozova L, Sevcikova S, Pour L.

Klin Onkol. 2019 Fall;32(6):445-452. doi: 10.14735/amko2019445.

PMID:
31842563
3.

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J.

Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.

PMID:
31836199
4.

Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data.

Stork M, Sevcikova S, Brozova L, Spicka I, Maisnar V, Minarik J, Jungova A, Gregora E, Velichova R, Hajek R, Jelinek T, Pour L.

Neoplasma. 2020 Jan;67(1):178-184. doi: 10.4149/neo_2019_190430N383. Epub 2019 Dec 9.

PMID:
31829027
5.

Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.

Vrabel D, Sedlarikova L, Besse L, Rihova L, Bezdekova R, Almasi M, Kubaczkova V, Brožová L, Jarkovsky J, Plonkova H, Jelinek T, Sandecka V, Stork M, Pour L, Sevcikova S, Hajek R.

Eur J Haematol. 2020 Mar;104(3):190-197. doi: 10.1111/ejh.13358. Epub 2019 Dec 20.

PMID:
31763708
6.

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.

Campioni M, Agirrezabal I, Hajek R, Minarik J, Pour L, Spicka I, Gonzalez-McQuire S, Jandova P, Maisnar V.

Eur J Health Econ. 2019 Oct 31. doi: 10.1007/s10198-019-01122-6. [Epub ahead of print]

PMID:
31673898
7.

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination.

Garcés JJ, Simicek M, Vicari M, Brozova L, Burgos L, Bezdekova R, Alignani D, Calasanz MJ, Growkova K, Goicoechea I, Agirre X, Pour L, Prosper F, Rios R, Martinez-Lopez J, Millacoy P, Palomera L, Del Orbe R, Perez-Montaña A, Garate S, Blanco L, Lasa M, Maiso P, Flores-Montero J, Sanoja-Flores L, Chyra Z, Vdovin A, Sevcikova T, Jelinek T, Botta C, El Omri H, Keats J, Orfao A, Hajek R, San-Miguel JF, Paiva B.

Leukemia. 2020 Feb;34(2):589-603. doi: 10.1038/s41375-019-0588-4. Epub 2019 Oct 8.

PMID:
31595039
8.

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.

Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, Hajek R, Gunsilius E, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Rumpold H, Pour L, Jelinek T, Krenosz KJ, Meckl A, Nolte S, Melchardt T, Greil R, Zojer N.

Leuk Lymphoma. 2020 Feb;61(2):377-386. doi: 10.1080/10428194.2019.1666381. Epub 2019 Sep 26.

PMID:
31556753
9.

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.

Hájek R, Delforge M, Raab MS, Schoen P, DeCosta L, Spicka I, Radocha J, Pour L, Gonzalez-McQuire S, Bouwmeester W.

Br J Haematol. 2019 Nov;187(4):447-458. doi: 10.1111/bjh.16105. Epub 2019 Aug 6.

10.

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.

Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O'Rourke L, Dimopoulos MA.

Haematologica. 2020 Jan 31;105(2):468-477. doi: 10.3324/haematol.2019.217448. Print 2020.

11.

Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma.

Deulofeu M, Kolářová L, Salvadó V, María Peña-Méndez E, Almáši M, Štork M, Pour L, Boadas-Vaello P, Ševčíková S, Havel J, Vaňhara P.

Sci Rep. 2019 May 28;9(1):7975. doi: 10.1038/s41598-019-44215-1.

12.

Extramedullary disease in multiple myeloma - controversies and future directions.

Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R.

Blood Rev. 2019 Jul;36:32-39. doi: 10.1016/j.blre.2019.04.002. Epub 2019 Apr 13. Review.

13.

Systemic inflammatory response with high CRP values as the dominant symptom of multiple myeloma.

Král Z, Adam Z, Folber F, Moulis M, Tomíška M, Říhová L, Štork M, Buliková A, Pour L, Krejčí M, Sandecká V, Koukalová R, Řehák Z, Čermáková Z.

Vnitr Lek. Winter 2019;65(1):37-44.

PMID:
30823836
14.

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J.

Blood. 2019 May 2;133(18):1953-1963. doi: 10.1182/blood-2018-09-874396. Epub 2019 Feb 28.

PMID:
30819926
15.

Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.

Maisnar V, Stefanikova Z, Spicka I, Pour L, Minarik J, Flochova E, Radocha J, Gregora E, Stecova N, Jelinek T, Jungova A, Kralikova E, Brozova L, Hajek R.

Neoplasma. 2019 May 23;66(3):499-505. doi: 10.4149/neo_2018_180824N644. Epub 2019 Feb 14.

PMID:
30784289
16.

Epidemiology of Plasma Cell Leukemia in the Czech Republic.

Zapletalova M, Krejci D, Jarkovský J, Muzik J, Dusek L, Pour L.

Klin Onkol. Winter 2019;32(1):47-51. doi: 10.14735/amko2019.

PMID:
30764629
17.

Plasma Cell Leukemia –  the Forgotten Dis­ease

Žárska M, Vrábel D, Bezdekova R, Štork M, Jarošová M, Adam Z, Krejčí M, Pour L, Ševčíková S.

Klin Onkol. Winter 2019;32(1):40-46. Review.

PMID:
30764628
18.

Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis.

Radocha J, Hájek R, Brožová L, Pour L, Špička I, Minařík J, Gregora E, Jungová A, Jelínek T, Heindorfer A, Sýkora M, Maisnar V.

Ann Hematol. 2019 Apr;98(4):951-962. doi: 10.1007/s00277-018-3568-2. Epub 2018 Dec 11.

PMID:
30539278
19.

The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma.

Vrábel D, Pour L, Ševčíková S.

Blood Rev. 2019 Mar;34:56-66. doi: 10.1016/j.blre.2018.11.003. Epub 2018 Nov 23. Review.

20.

Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients.

Almasi M, Besse L, Brozova L, Jarkovsky J, Bezdekova R, Pour L, Minarik J, Kessler P, Pavlíček P, Roziakova L, Penka M, Hájek R, Vasku A, Sevcikova S.

Klin Onkol. Spring 2018;31(3):213-229. doi: 10.14735/amko2018213.

PMID:
30441975
21.

Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population.

Minarik J, Pour L, Maisnar V, Spicka I, Jungova A, Jelinek T, Brozova L, Krhovska P, Scudla V, Hajek R.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Sep;163(3):279-283. doi: 10.5507/bp.2018.064. Epub 2018 Nov 6.

22.

Circulating exosomal long noncoding RNA PRINS-First findings in monoclonal gammopathies.

Sedlarikova L, Bollova B, Radova L, Brozova L, Jarkovsky J, Almasi M, Penka M, Kuglík P, Sandecká V, Stork M, Pour L, Sevcikova S.

Hematol Oncol. 2018 Dec;36(5):786-791. doi: 10.1002/hon.2554. Epub 2018 Sep 13.

23.

Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients.

Stork M, Sevcikova S, Adam Z, Krejci M, Sandecka V, Kral Z, Brozova L, Velichova R, Pour L.

Neoplasma. 2018;65(4):585-591. doi: 10.4149/neo_2018_170519N363.

PMID:
29940759
24.

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.

Radocha J, Maisnar V, Pour L, Špička I, Minařík J, Szeligová L, Pavlíček P, Jungová A, Krejčí M, Pika T, Straub J, Brožová L, Stejskal L, Heindorfer A, Jindra P, Kessler P, Mikula P, Sýkora M, Wróbel M, Jarkovský J, Hájek R.

Cancer Med. 2018 Aug;7(8):4132-4145. doi: 10.1002/cam4.1620. Epub 2018 Jun 21.

25.

[MicroRNA Analysis for Extramedullary Multiple Myeloma Relapse].

Gregorová J, Vrábel D, Radová L, Gablo NA, Almaši M, Štork M, Slabý O, Pour L, Minařík J, Ševčíková S.

Klin Onkol. Spring 2018;31(Supplementum1):148-150. Czech.

PMID:
29808690
26.

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.

Hájek R, Jarkovsky J, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Campioni M, DeCosta L, Treur M, Gonzalez-McQuire S, Bouwmeester W.

Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):e219-e240. doi: 10.1016/j.clml.2018.04.003. Epub 2018 Apr 17.

PMID:
29793653
27.

[Heart transplantation and follow-up treatment with AL-amyloidosis in 5 patients].

Adam Z, Ozábalová E, Němec P, Bedáňová H, Kuman M, Krejčí J, Špinarová L, Žampachová V, Čermáková Z, Pour L, Krejčí M, Sanecká V, Štork M, Pika T, Straub J, Adamová D, Stavařová Y, Král Z, Mayer J.

Vnitr Lek. Spring 2018;64(4):441-449. Czech.

PMID:
29791180
28.

[Remission of the disease associated/related with immunoglobulin IgG4 accompanied by multiple lymphadenopathy after treatment with rituximab and dexamethasone: a case report].

Adam Z, Chovancová Z, Nová M, Fabian P, Řehák Z, Koukalová R, Slávik M, Pour L, Krejčí M, Čermák A, Král Z, Mayer J.

Vnitr Lek. Spring 2018;64(3):290-299. Czech.

PMID:
29766732
29.

Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse.

Smetana J, Oppelt J, Štork M, Pour L, Kuglík P.

Mol Cytogenet. 2018 Jan 18;11:7. doi: 10.1186/s13039-018-0357-5. eCollection 2018.

30.

[Remission of steroid-resistant Stills disease treated with anakinra, evidenced by FDG-PET/CT examination: case report].

Adam Z, Skřičková J, Krtička M, Řehák Z, Koukalová R, Šprláková A, Krejčí M, Pour L, Adamová Z, Pourová E, Král Z.

Vnitr Lek. Winter 2018;63(12):987-997. Czech.

PMID:
29334750
31.

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators.

N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.

32.

Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.

Jelínek T, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Adamová D, Wróbel M, Mikula P, Jarkovský J, Diels J, Gatopoulou X, Veselá Š, Besson H, Brožová L, Ito T, Hájek R.

Curr Med Res Opin. 2018 May;34(5):775-783. doi: 10.1080/03007995.2017.1410121. Epub 2018 Feb 15.

PMID:
29172760
33.

[The benefit of new angiogenesis (bevacizumab and aflibercept) inhibitors for multiple angiomatosis therapy: a case report].

Brančíková D, Ostřížková L, Adam Z, Nebeský T, Pour L, Král Z, Mayer J.

Vnitr Lek. Fall 2017;63(10):672-678. Czech.

PMID:
29127751
34.

Mannose-Binding Lectin Protein Deficiency Among Patients with Primary Immunodeficiency Disease Receiving IVIG Therapy.

Azizi G, Kiaee F, Yaslianifard S, Rafiemanesh H, Mohammadikhajehdehi S, Mohammadi H, Miresmaeeli SS, Pour LH, Poor Heravi SA, Sharifi L, Yazdani R, Abolhassani H, Aghamohammadi A.

Endocr Metab Immune Disord Drug Targets. 2018 Feb 13;18(2):175-183. doi: 10.2174/1871530317666171108111749.

PMID:
29119939
35.

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG.

Blood. 2017 Dec 14;130(24):2610-2618. doi: 10.1182/blood-2017-06-791228. Epub 2017 Oct 20.

PMID:
29054911
36.

Whole Exome Sequencing of Aberrant Plasma Cells in a Patient with Multiple Myeloma Minimal Residual Disease.

Zatopkova M, Filipová J, Jelínek T, Vojta P, Sevcikova T, Simicek M, Rihova L, Bezdekova R, Growkova K, Kufová Z, Smejkalová J, Hajdúch M, Pour L, Minárik J, Jungová A, Maisnar V, Kryukov F, Hájek R.

Klin Onkol. Summer 2017;30(Supplementum2):75-80. doi: 10.14735/amko20172S75.

PMID:
28903574
37.

Biomarkers in Immunoglobulin Light Chain Amyloidosis.

Kufová Z, Sevcikova T, Growkova K, Vojta P, Filipová J, Adam Z, Pour L, Penka M, Rysava R, Němec P, Brozova L, Vychytilova P, Jurczyszyn A, Grosicki S, Barchnicka A, Hajdúch M, Simicek M, Hájek R.

Klin Onkol. Summer 2017;30(Supplementum2):60-67. doi: 10.14735/amko20172S60.

PMID:
28903572
38.

Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies.

Brozova L, Jarkovský J, Pour L, Minárik J, Jungová A, Gregora E, Spicka I, Maisnar V, Hájek R.

Klin Onkol. Summer 2017;30(Supplementum2):51-59. doi: 10.14735/amko20172S51.

PMID:
28903571
39.

Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation.

Brozova L, Schwarz D, Snabl I, Kalina J, Pavlickova B, Komenda M, Jarkovský J, Němec P, Horinek D, Stefanikova Z, Pour L, Hájek R, Maisnar V.

Klin Onkol. Summer 2017;30(Supplementum2):43-50. doi: 10.14735/amko20172S43.

PMID:
28903570
40.

Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.

Rihova L, Vsianska P, Bezdekova R, Kralova R, Penka M, Krejci M, Pour L, Hájek R.

Klin Onkol. Summer 2017;30(Supplementum2):21-28. doi: 10.14735/amko20172S21. Review.

PMID:
28903567
41.

Liquid Biopsies - the Clinics and the Molecules.

Kubaczková V, Sedlarikova L, Bollová B, Sandecká V, Stork M, Pour L, Sevcikova S.

Klin Onkol. Summer 2017;30(Supplementum2):13-20. doi: 10.14735/amko20172S13. Review.

PMID:
28903565
42.

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.

Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P.

Haematologica. 2017 Oct;102(10):1767-1775. doi: 10.3324/haematol.2017.170118. Epub 2017 Jul 27.

43.

[Osteoprotective therapy with bisphosphonates or denosumab in patients with multiple myeloma: benefit and risks].

Adam Z, Straub J, Krejčí M, Pour L, Brančíková D, Ostřížková L, Sandecká V, Štork M.

Vnitr Lek. Summer 2017;63(5):311-321. Review. Czech.

PMID:
28726429
44.

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.

Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA.

Haematologica. 2017 Sep;102(9):1617-1625. doi: 10.3324/haematol.2017.163766. Epub 2017 May 26.

45.

Deregulated expression of long non-coding RNA UCA1 in multiple myeloma.

Sedlarikova L, Gromesova B, Kubaczkova V, Radova L, Filipova J, Jarkovsky J, Brozova L, Velichova R, Almasi M, Penka M, Bezdekova R, Stork M, Adam Z, Pour L, Krejci M, Kuglík P, Hajek R, Sevcikova S.

Eur J Haematol. 2017 Sep;99(3):223-233. doi: 10.1111/ejh.12908. Epub 2017 Jun 29.

PMID:
28543758
46.

[Indeterminate cell histiocytosis - disappearance of skin infiltration following electron beam therapy and an application of 2-chlorodeoxyadenosine: case report].

Adam Z, Ježová M, Šlampa P, Křen L, Vašků V, Koukalová R, Řehák Z, Pour L, Krejčí M, Král Z, Mayer J.

Vnitr Lek. Spring 2017;63(4):284-288. Czech.

PMID:
28520453
47.

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.

Sandecká V, Hájek R, Pour L, Špička I, Ščudla V, Gregora E, Radocha J, Walterová L, Kessler P, Zahradová L, Adamová D, Valentova K, Vonke I, Obernauerová J, Starostka D, Wróbel M, Brožová L, Jarkovský J, Mikulášová A, Říhová L, Ševčíková S, Straub J, Minařík J, Adam Z, Krejčí M, Král Z, Maisnar V; Czech Myeloma Group.

Eur J Haematol. 2017 Jul;99(1):80-90. doi: 10.1111/ejh.12894. Epub 2017 May 11.

PMID:
28384387
48.

IgM myeloma: A multicenter retrospective study of 134 patients.

Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA.

Am J Hematol. 2017 Aug;92(8):746-751. doi: 10.1002/ajh.24753. Epub 2017 May 26.

49.

Genomewide association study on monoclonal gammopathy of unknown significance (MGUS).

Thomsen H, Campo C, Weinhold N, da Silva Filho MI, Pour L, Gregora E, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, Hajek R, Goldschmidt H, Hemminki K, Försti A.

Eur J Haematol. 2017 Jul;99(1):70-79. doi: 10.1111/ejh.12892. Epub 2017 May 24.

PMID:
28375557
50.

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

Ludwig H, Dimopoulos MA, Moreau P, Chng WJ, Goldschmidt H, Hájek R, Facon T, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Palumbo A, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Joshua D.

Leuk Lymphoma. 2017 Oct;58(10):2501-2504. doi: 10.1080/10428194.2017.1298755. Epub 2017 Mar 17. No abstract available.

PMID:
28306371

Supplemental Content

Support Center